Life Science News

Danaher Corporation (NYSE: DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members.

Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners.

Mr. Dewan earned his B.S. in Engineering with a Certificate in Applied and Computational Mathematics from Princeton University .

Steven M. Rales, Chairman of the Board of Danaher Corporation, said "We are very pleased to welcome Feroz to the Board. We expect that his financial acumen and technology expertise will be a tremendous benefit to Danaher as we strive to continue building sustainable, long-term value for all of our constituents."

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 80,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com .

Cision View original content: https://www.prnewswire.com/news-releases/danaher-announces-appointment-of-feroz-dewan-to-danaher-board-301578322.html

SOURCE Danaher Corporation

News Provided by PR Newswire via QuoteMedia

DHR

INN Video: Ian Graham of Discovery Harbour Resources

Discovery Harbour Resources Corp. (TSXV:DHR) President and CEO, Ian Graham, spoke with Resource Investing News on its flagship project, Wabassi, located in northern Ontario. “We’ve put our arms around an entire Greenstone Belt hosted VMS Mineral District. This is, as far as I’m aware, Canada’s most recent discovery of a new mineral district,” states Mr. Graham. In 2013, investors can expect the mobilization of drilling on the project, with news expected to come out in July. “Based on that news, we will be financing the Company a little further in the fall,” Mr. Graham says.

Keep reading...Show less

Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) ("the Company") announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.

Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D, and the Company thanks Dr. Mammen for his contributions in advancing Johnson & Johnson's industry-leading portfolio. The Company will continue to prioritize innovation and building new capabilities to improve the lives of the patients and consumers we serve worldwide.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Avricore Health

Healthtab™ Expands With Shoppers Drug Mart®

AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to announce that the Company is significantly expanding the number of Shoppers Drug Mart pharmacies offering its HealthTab point-of-care testing platform under a renewed Master Service Agreement (MSA) to up to 450 locations nation-wide.

In addition to Shoppers Drug Mart pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize HealthTab upon request.

Keep reading...Show less

Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals

  • Two industry leaders join forces to empower people living with diabetes by providing information and insights to improve weight loss, glucose control and overall health
  • Collaboration will create a seamless, integrated experience between Abbott's world-leading continuous glucose monitoring device 1 and WeightWatchers' number one doctor-recommended weight loss program 2 to help individuals better understand and manage their diabetes and weight

Abbott (NYSE: ABT) and WW International, Inc. ("WeightWatchers" or "WW") today announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight. The companies are working together to integrate WeightWatchers' diabetes-tailored weight management program with Abbott's portfolio of FreeStyle Libre ® products to create a seamless mobile experience that will give people living with diabetes the information and insights needed to make healthy adjustments to their diet, improve their glucose levels, and, ultimately, gain more control of their health.

Maintaining a healthy body weight and having proper nutrition are critical to living well with diabetes. 3 Yet, for many people living with diabetes, determining what to eat and following a meal plan is the most challenging part of diabetes management. 4 Through this partnership, participants can receive glucose insights from Abbott's FreeStyle Libre sensor-based technology that show the impact of food choices, alongside the empirically validated 5 WeightWatchers' diabetes-tailored nutritional guidance to help them achieve their healthier living goals.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2022 financial results on Thursday, August 11, 2022 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, August 11, 2022

Time : 8:30 a.m. ET

Telephone : Toll Free: 1-855-669-9657 or International 1-412-317-0790

Webcast : www.gud- knight .com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay : An archived replay will be available for 30 days at www.gud-knight.com .


________________________________________
About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET. A copy of the investor presentation will be available at www.gud-knight.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis

New Embedded CryoSPARC Live software to be made available by Structura and Thermo Fisher and designed to integrate with Thermo Fisher technology

Thermo Fisher Scientific Inc., the world leader in serving science, and Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, today announced a collaboration to make available a new single particle analysis software solution, a version of Structura's CryoSPARC Live, that is designed to integrate with Thermo Fisher's Smart EPU software and cryo-transmission electron microscope (cryo-TEM) technology. The new solution, Embedded CryoSPARC Live , will be offered as a subscription.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×